ArticleInternational urology and nephrology2026
More work for the same pay: trends in urethroplasty reimbursement from the medicare physician fee schedule (2013-2023).
Article in International urology and nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesUrethroplasty is the gold standard for recurrent urethral stricture disease per the 2016 American Urological Association (AUA) guideline. Its sustainability depends on economic viability; however, recent payment cuts and inflationary pressures threaten reimbursement. This study analyzed: (1) trends in Medicare providers performing urethroplasty, (2) urethroplasty procedure volumes, and (3) nominal and inflation-adjusted Medicare reimbursement from 2013-2023, contextualized against comparator urologic procedures.
methodsThis was a retrospective, cross-sectional study using the Centers for Medicare & Medicaid Services (CMS) Physician Fee Schedule and Medicare Part B Physician and Other Practitioners datasets from 2013-2023. Urethroplasty procedures were identified using CPT codes 53,400, 53,405, 53,410, 53,415, and 53,430. Comparator procedures included Cystourethroscopy with Direct Vision Internal Urethrotomy (DVIU, CPT 52276) and Endoscopic/Robotic-Assisted Radical Prostatectomy (CPT 55866). Reimbursement values were adjusted to August 2025 U.S. dollars using the Consumer Price Index.
resultsUrethroplasty provider numbers and procedure volumes increased 33-45% and 36-65%, respectively. Nominal urethroplasty reimbursement remained stable (-2.5% to + 22.8%), while inflation-adjusted reimbursement declined 18-25% across all types. By contrast, DVIU demonstrated declining provider participation (-33.9%) and procedure volumes (-46.5%), with inflation-adjusted reimbursement declining 27.4%. Endoscopic prostatectomy showed growing provider participation (+ 33.4%) and volumes (+ 27.3%), but experienced the most severe nominal (-26.5%) and inflation-adjusted (-43.5%) reimbursement decline of all procedures examined.
conclusionsUrethroplasty faces a distinctive economic burden: rising clinical demand paired with stagnant nominal and substantially declining real reimbursement. While reimbursement erosion affects all urologic procedures studied, the combination of increasing utilization and inadequate payment adjustment is uniquely pronounced for reconstructive urology. Long-term sustainability will require reimbursement models that align payment with evidence-based, high-value surgical care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.